Evidence supporting the use of: Boswellic acids
For the health condition: Crohn's Disease

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Boswellic acids, derived from the resin of Boswellia serrata (frankincense), have been investigated for their anti-inflammatory properties, particularly in chronic inflammatory diseases. Several small clinical studies and preclinical models have explored their effects in inflammatory bowel diseases, including Crohn’s disease. Boswellic acids inhibit 5-lipoxygenase, an enzyme involved in leukotriene synthesis, which plays a role in inflammatory processes in the gut.

A few randomized controlled trials have assessed Boswellia extract in ulcerative colitis and Crohn’s disease. For Crohn’s disease specifically, a notable double-blind, placebo-controlled study (Gerhardt et al., 2001) reported that Boswellia extract (containing 350 mg boswellic acids thrice daily) showed similar rates of remission compared to mesalazine, a standard therapy, although the sample size was modest. Other studies have been limited by small size or methodological quality.

Systematic reviews and meta-analyses (e.g., Langmead & Rampton, 2006; Gupta et al., 2001) suggest potential benefit, but also emphasize that the evidence base is weak and larger, well-designed trials are needed. There are no established clinical guidelines recommending boswellic acids for Crohn’s disease. Thus, while there is some scientific rationale and limited clinical data, the overall quality and quantity of evidence are low, justifying a modest evidence rating.

More about Boswellic acids
More about Crohn's Disease

Products containing Boswellic acids

We currently have no products on Vitabase that contain this ingredient.